A LinkedIn post from Neuromod Devices Ltd highlights that its Lenire tinnitus treatment device is now available in the Netherlands through HearConsult locations in Utrecht and Mijdrecht. The post notes this expansion targets a market where over 2 million adults are affected by tinnitus and cites research indicating a 33% increase in tinnitus incidence between 2012 and 2021, particularly among adults aged 20 to 44.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references a positive user experience from an Utrecht-based researcher and points readers to further coverage in The Hearing Review, suggesting efforts to build clinical and professional awareness. For investors, this development implies incremental geographic expansion, growing addressable market exposure in a country with rising tinnitus prevalence, and potential reinforcement of Lenire’s clinical positioning within the audiology and hearing-care ecosystem.